Post Magazine: Medical Marvel
The News Review:
- Post Magazine: Medical Marvel
- Buying a Cure.(Kathy Giusti’s Multiple Myeloma Research Foundation…
- Common drug tested as diabetes preventive measure
- Anti-clotting drug trial shortened by bleeding problems
Post Magazine: Medical Marvel
Washington Post – Jan 28, 2008
My contribution at Dr. McDonald’s facility also involves patients fund raising and public relations. Initial clinical research conducted in St. Louis is currently being written for publication. It found that 69% of patients responded to activity-based advanced restorative therapies including increased muscle mass and muscle strength and notable gains in motor and sensory function. _______________________Greenbelt Md. : Does handedness play a factor in motor recovery?Pat Rummerfield: Sometimes it can make certain rehab efforts more challenging but there is no evidence that I know of that it inhibits motor recovery.
Buying a Cure.(Kathy Giusti’s Multiple Myeloma Research Foundation…
Free with registration – New Yorker – AccessMyLibrary.com – Jan 28, 2008
(Kathy Giusti’s Multiple Myeloma Research Foundation) –>CPYRIGHT 2008 All rights reserved. Reproduced by permission of The Condé Nast Publications Inc. Last May Kathy Giusti was in midtown Manhattan pitching her current venture to an audience of potential investors. Giusti a forty-eight-year-old Harvard Business School graduate and former pharmaceutical executive believes that medical breakthroughs shouldn’t be left to chance. In 1998 she created the Multiple Myeloma Research Foundation a charitable organization dedicated to the lethal blood cancer which afflicts more than fifty thousand Americans and has no known cure. Most medical charities focus on increasing public awareness and on raising money to distribute to researchers in the hope that some of the work will lead to a new drug or a cure; Giusti runs hers as if it were a for-profit business expecting high returns on the money she raises from “investors”–her term for philanthropists. Her staff includes four scientists who track myeloma research at academic institutions around the world advising her on which projects are most likely to lead to new therapies for patients and are thus the best candidates for funding.
Common drug tested as diabetes preventive measure
Pittsburgh Post-Gazette – Pittsburgh Post Gazette – Jan 29, 2008
Goldfine lead researcher in the study said the findings are “exciting and promising” because they show that salsalate “may be useful in preventing diabetes. She is head of clinical research at Joslin and assistant professor at Harvard Medical School. Salsalate is a nonsteroidal anti-inflammatory drug long used to treat arthritis. But Joslin research shows evidence that it lowers blood-sugar levels in people with type 2 who have problems producing and effectively using their own insulin. Aspirin has a similar beneficial impact on diabetes but would require an unsafe daily dose. So researchers sought a safe alternative from the same family of drugs.
Anti-clotting drug trial shortened by bleeding problems
Tehran Times – Jan 28, 2008
26 issue of The Lancet. To outside observers that was a depressing repeat of studies reported last September that showed the drug to be effective against deep vein thrombosis and long-term prevention of blood clots but with a high rate of serious bleeding complications. “”This is clearly a setback”" said Dr. Alan Go associate director for clinical research at Kaiser Permanente of Northern California co-author of an accompanying editorial in the journal. Go like other experts in the field acknowledged that “”we are eager to find a replacement for warfarin. It is a remarkably effective drug but challenging to deliver and challenging to take. “”Buller said that if all turns out as well as he hopes idraparinux could be a useful alternative for many people who could get the needed anti-clotting activity with a single weekly injection while forgoing the constant blood tests required for warfarin users.
Written by admin on January 29th, 2008 with
no comments.
Read more articles on News.